Global Pharmerging Market

Pharmerging Market by Products (Pharmaceutical [OTC Drugs, Generic Prescription Drug and Patented Prescription Drugs] and Other Healthcare Verticals [Clinical Diagnostics, Medical device, and Others]) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2195
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 176
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global pharmerging market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing number of private hospitals and increasing healthcare expenditure.


Global Pharmerging Market summary

Pharmerging is a term referred to a range of countries that have low or less development position in the pharmaceutical industry yet they have a fast income growth. Some of the main pharmerging markets are India, Brazil, Russia, China, Mexico, Indonesia, Turkey, and South Africa. The rise of population in these countries plays an important role in influencing the overall market growth. Additionally, growing the aging population acts as another main factor for the market expansion. Among every sixth person one person is expected to get over the age of 60 by 2030, as per a study by a global health organization. Geriatric population is expected to increase to 310 million by 2050 in China and crossing 275 million by 2050 in India. Most common diseases in the geriatric population include cardiac failure, hypertension, and dementia. These diseases require continuous and prolonged treatment. 

The demand for second care and home healthcare is rising among the geriatric population. There has been a rapid development in the healthcare facilities especially in major emerging economies such as Brazil, China, and India whereas these facilities are both privately as well as government funded. Governments across other countries have also increased healthcare expenditure and implemented supportive policies in order to decrease the cost of treatment for chronic diseases.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing number of private hospitals, increasing healthcare expenditure, and increasing number of chronic diseases are expected to boost the market growth in the coming years.
  • Rising the geriatric population and gradual development of healthcare facilities especially the pharmaceutical industry are positively influencing the market growth.
  • Availability of low-cost home healthcare system and expansion of several pharmaceutical manufacturing units in these countries are further expected to fuel the market expansion.
  • Favorable government policies and healthcare initiatives to decrease the treatment cost for chronic diseases are expected to spur the market growth.
  • Price sensitivity of the pharmaceutical products and lack of awareness for disease prevention or treatment are expected to hamper the market expansion during the forecast period.

Scope of the Report                          

The report on the global pharmerging market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pharmerging Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Pharmaceutical [OTC Drugs, Generic Prescription Drug, and Patented Prescription Drugs] and Other Healthcare Verticals [Clinical Diagnostics, Medical Device, and Others])

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Pfizer Inc.; AstraZeneca Plc; GlaxoSmithKline Plc; SANOFI-Synthelabo (India) Private Limited; F.Hoffmann-La Roche AG; Eli Lilly and Company; Medtronic; Johnson and Johnson; Abbott Healthcare; and GE Healthcare.

Market Segment Insights

Pharmaceutical segment is expected to grow at a rapid pace

Based on products, the global pharmerging market is bifurcated into pharmaceutical and other healthcare verticals. The pharmaceutical segment is further divided into OTC drugs, generic prescription drug, and patented prescription drugs, while the other healthcare verticals segment is sub-divided into clinical diagnostics, medical device, and others. The pharmaceutical segment is expected to grow at a rapid pace of the market in the coming years owing to rising healthcare expenditure and price sensitivity of pharmaceutical products. However, the other healthcare verticals segment is anticipated to expand at a healthy growth rate during the forecast period due to wide range of products and services available in the market for medical devices.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market during the projected period owing to rising demand of products and services by pharmaceutical vendors in the region. Meanwhile, the market of Asia Pacific is anticipated to expand at a high CAGR during the forecast period due to recent industry developments and supporting government policies in the region.


Global Pharmerging Market region

Segments

Segments Covered in the Report
The global pharmerging market has been segmented on the basis of
Applications

  • Pharmaceutical
    • OTC Drugs
    • Generic Prescription Drug
    • Patented Prescription Drugs
  • Other Healthcare Verticals
    • Clinical Diagnostics
    • Medical Device
    • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Pfizer Inc.
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • SANOFI-Synthelabo (India) Private Limited
  • F.Hoffmann-La Roche AG
  • Eli Lilly and Company
  • Medtronic
  • Johnson and Johnson
  • Abbott Healthcare
  • GE Healthcare

 

Competitive Landscape

Key players competing in the pharmerging market are Pfizer Inc.; AstraZeneca Plc; GlaxoSmithKline Plc; SANOFI-Synthelabo (India) Private Limited; F.Hoffmann-La Roche AG; Eli Lilly and Company; Medtronic; Johnson and Johnson; Abbott Healthcare; and GE Healthcare.

Some of these main players are continuously engaged in various business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market positions. For instance, SANOFI-Synthelabo (India) Private Limited signed a transaction with Boehringer Ingelheim for the exchange of Sanofi’s animal health business and BI’s consumer healthcare business in January 2017.

Global Pharmerging Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pharmerging Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pharmerging Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pharmerging Market - Supply Chain
  4.5. Global Pharmerging Market Forecast
     4.5.1. Pharmerging Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pharmerging Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pharmerging Market Absolute $ Opportunity
5. Global Pharmerging Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Pharmerging Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Pharmerging Demand Share Forecast, 2019-2026
6. North America Pharmerging Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Pharmerging Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Pharmerging Demand Share Forecast, 2019-2026
7. Latin America Pharmerging Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Pharmerging Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Pharmerging Demand Share Forecast, 2019-2026
8. Europe Pharmerging Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Pharmerging Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Pharmerging Demand Share Forecast, 2019-2026
9. Asia Pacific Pharmerging Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Pharmerging Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Pharmerging Demand Share Forecast, 2019-2026
10. Middle East & Africa Pharmerging Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Pharmerging Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Pharmerging Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Pharmerging Market: Market Share Analysis
  11.2. Pharmerging Distributors and Customers
  11.3. Pharmerging Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Pfizer Inc.
     11.4.2. AstraZeneca Plc
     11.4.3. GlaxoSmithKline Plc
     11.4.4. SANOFI-Synthelabo (India) Private Limited
     11.4.5. F.Hoffmann-La Roche AG
     11.4.6. Eli Lilly and Company
     11.4.7. Medtronic

Segments Covered in the Report
The global pharmerging market has been segmented on the basis of
Applications

  • Pharmaceutical
    • OTC Drugs
    • Generic Prescription Drug
    • Patented Prescription Drugs
  • Other Healthcare Verticals
    • Clinical Diagnostics
    • Medical Device
    • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Pfizer Inc.
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • SANOFI-Synthelabo (India) Private Limited
  • F.Hoffmann-La Roche AG
  • Eli Lilly and Company
  • Medtronic
  • Johnson and Johnson
  • Abbott Healthcare
  • GE Healthcare

 

Key players competing in the pharmerging market are Pfizer Inc.; AstraZeneca Plc; GlaxoSmithKline Plc; SANOFI-Synthelabo (India) Private Limited; F.Hoffmann-La Roche AG; Eli Lilly and Company; Medtronic; Johnson and Johnson; Abbott Healthcare; and GE Healthcare.

Some of these main players are continuously engaged in various business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market positions. For instance, SANOFI-Synthelabo (India) Private Limited signed a transaction with Boehringer Ingelheim for the exchange of Sanofi’s animal health business and BI’s consumer healthcare business in January 2017.

Global Pharmerging Market keyplayers

Buy Report